ライフサイエンスコーパス: hysterectomy

1 tomy, reflux surgery, bariatric surgery, and hysterectomy).

2 nonbariatric surgery (i.e., cholecystectomy, hysterectomy).

3 tions in postmenopausal women who have had a hysterectomy.

4 our samples were obtained at recruitment and hysterectomy.

5 n major procedure for women in the U.S., the hysterectomy.

6 ociations between PFC levels and the rate of hysterectomy.

7 tes, aged 50 to 79 years, who did not have a hysterectomy.

8 ta previa and accreta, and consequent gravid hysterectomy.

9 tions in postmenopausal women who have had a hysterectomy.

10 associated with increased chance of radical hysterectomy.

11 , or its costs compared with other routes of hysterectomy.

12 the internal os at MR imaging needed radical hysterectomy.

13 uterine or vaginal vault prolapse following hysterectomy.

14 0-$2349) more per case than for laparoscopic hysterectomy.

15 tomy and 1,437 (58.3%) who underwent robotic hysterectomy.

16 ut increased cost compared with laparoscopic hysterectomy.

17 ge, race, breast cancer risk, and history of hysterectomy.

18 lization only or partial ovariectomy without hysterectomy.

19 emale genital tract and the leading cause of hysterectomy.

20 l are similar for all the methods of radical hysterectomy.

21 al women with endometrial cancer who undergo hysterectomy.

22 women with endometrial cancer who underwent hysterectomy.

23 ecause of previous colectomy, mastectomy, or hysterectomy.

24 ated, stratifying by study, age, parity, and hysterectomy.

25 s of the smooth muscle, are a major cause of hysterectomy.

26 incidence in postmenopausal women with prior hysterectomy.

27 that is not curable by any extent of radical hysterectomy.

28 mportant chiefly as the major indication for hysterectomy.

29 rectomy, and 1458 (19.0%) had a laparoscopic hysterectomy.

30 for most postmenopausal women who have had a hysterectomy.

31 tial risk profile of women who had undergone hysterectomy.

32 nonfatal CVD were higher among women with a hysterectomy.

33 mpare the costs and effectiveness of UAE and hysterectomy.

34 ve (US dollars 6916 vs US dollars 7847) than hysterectomy.

35 0%) had a reoperation within 30 days after a hysterectomy.

36 s, and blood transfusion within 30 days of a hysterectomy.

37 esidual confounding, such as the reasons for hysterectomy.

38 c subtypes in BRCA+ women after RRSO without hysterectomy.

39 nderwent RRSO without a prior or concomitant hysterectomy.

40 for 20 years; this was stopped in 2013 after hysterectomy.

41 Data were collected from 62 cases of hysterectomy.

42 sted hysterectomy accounted for 22.4% of all hysterectomies.

43 morbidities, and most common indication for hysterectomies.

44 ttraction to the use of robotics for radical hysterectomies.

45 n across operations (Pearson rho: intestinal-hysterectomy = 0.50, intestinal-endovascular = 0.36, hys

46 .001), colectomy (9.3% vs 15.0%; P < .001), hysterectomy (1.8% vs 3.9%; P < .001), and radical prost

47 inal resection (6.5 vs 5.7 d, P < 0.001) and hysterectomy (1.9 vs 1.7 d, P < 0.001), but not endovasc

48 (95% CI, 0.85-0.90) after hysterectomy vs no hysterectomy, 1.63 (95% CI, 1.52-1.75) after any vs no H

49 967 (21.1%) versus 9906 (11.7%), P < 0.0001; hysterectomy, 1063 (33.2%) versus 6751 (17.0%), P < 0.00

50 (18.1%), ventral hernia repair (16.7%), and hysterectomy (13.4%).

51 lecystectomy 3-fold higher, appendectomy and hysterectomy 2-fold higher, and back surgery 50% higher

52 The median WTO wait time was higher for hysterectomy (21.6 weeks) than for UAE or MR imaging-gui

53 sted hysterectomy compared with laparoscopic hysterectomy (23.7% v 19.5%; P = .03).

54 ncluded women, 3714 (48.3%) had an abdominal hysterectomy, 2513 (32.7%) had a vaginal hysterectomy, a

55 tomy (25.8%), ventral hernia repair (26.5%), hysterectomy (28.8%), arthroplasty (18.8%), and lower ex

56 At hysterectomy, 32 patients had uterine corpus cancer and

57 cutaneous and uterine leiomyomas had a total hysterectomy, 44% at age < or =30 years.

58 imilar for robotic-assisted and laparoscopic hysterectomy (5.5% vs 5.3%; relative risk [RR], 1.03; 95

59 Women who had undergone prophylactic hysterectomy (61 women) and women who had undergone prop

60 uded 62 patients who had undergone abdominal hysterectomy, 74 who had undergone UAE, and 61 who had u

61 ndectomy (23%), cholecystectomy (16.4%), and hysterectomy (8.2%).

62 surgical window between cancer diagnosis and hysterectomy according to patient preference.

63 erectomy was performed, robotically assisted hysterectomy accounted for 22.4% of all hysterectomies.

64 UAE is a cost-effective alternative to hysterectomy across a wide range of assumptions about th

65 (adjusted OR = 2.17, 95% CI: 1.34, 3.52) and hysterectomy (adjusted OR = 1.75, 95% CI: 1.15, 2.66) we

66 Compared with hysterectomy alone, hysterectomy with BSO was not associ

67 Six women had hysterectomies and two women died.

68 ing 1,027 (41.7%) who underwent laparoscopic hysterectomy and 1,437 (58.3%) who underwent robotic hys

69 luding 4,139 (65.7%) who underwent abdominal hysterectomy and 2,165 (34.3%) who underwent minimally i

70 were ineligible because they had undergone a hysterectomy and 2271 because their endometrial thicknes

71 omyomata (UL) are the primary indication for hysterectomy and are 2-3 times more common in black than

72 cologic cancers associated with prophylactic hysterectomy and bilateral salpingo-oophorectomy in wome

73 e examination at the time of total abdominal hysterectomy and bilateral salpingo-oophorectomy reveale

74 e tumour debulking including total abdominal hysterectomy and bilateral salpingo-oophorectomy, and ad

75 Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often

76 iation between the use of minimally invasive hysterectomy and either overall (HR, 0.89; 95% CI, 0.75

77 mined the relationship between premenopausal hysterectomy and EOC in African-American women and explo

78 Although the inverse association between hysterectomy and epithelial ovarian cancer (EOC) was con

79 Women aged 50-79 years who had undergone hysterectomy and had expected 3-year survival and mammog

80 k of diabetes after stratification by age at hysterectomy and hormone therapy status.

81 r Pap smears that may have preceded a recent hysterectomy and hysterectomies that spared the cervix o

82 ctioning than did those treated with radical hysterectomy and lymph node dissection.

83 omectomy is not necessarily less morbid than hysterectomy and may have a greater failure rate than UA

84 The frequency of hysterectomy and of maternal death did not differ signif

85 vestigated the associations of premenopausal hysterectomy and oophorectomy with breast cancer risk.

86 idence supports the efficacy of prophylactic hysterectomy and oophorectomy.

87 ation-based analysis to compare laparoscopic hysterectomy and robotic hysterectomy for endometrial ca

88 could increase by approximately 4 years with hysterectomy and salpingo-oophorectomy and adherence to

89 stage I/IIA disease and procedure including hysterectomy and selective lymphadenectomy (pelvic or pe

90 sit (the first visit after the date of NM or hysterectomy) and after index visit until the end of fol

91 es during 8404 intestinal resections, 22,854 hysterectomies, and 1471 abdominopelvic endovascular pro

92 34.2%) partial nephrectomies, 14 047 (10.4%) hysterectomies, and 1782 (6.5%) oophorectomies.

93 appendectomy, 12.1% for colectomy, 2.8% for hysterectomy, and 1.7% for prostatectomy.

94 nal hysterectomy, 2513 (32.7%) had a vaginal hysterectomy, and 1458 (19.0%) had a laparoscopic hyster

95 e obtained on patients undergoing colectomy, hysterectomy, and knee and hip replacement procedures.

96 pen cholecystectomy, closed cholecystectomy, hysterectomy, and prostatectomy.

97 he medicine group had requested and received hysterectomy, and these women reported improvements in q

98 PFCs were positively associated with rate of hysterectomy, and time since natural menopause was posit

99 controls) who provided data on ovariectomy, hysterectomy, and tubal sterilization during in-person i

100 hrectomy; 8060, partial nephrectomy; 134985, hysterectomy; and 27445, oophorectomy.

101 than 65 years of age; women with a previous hysterectomy; and women who described their race or ethn

102 Varying rates of hysterectomy are a potentially important contributor to

103 Robotic sacrocolpopexy and hysterectomy are most commonly described, but the use of

104 Most US women who have undergone hysterectomy are not at risk of cervical cancer-they und

105 men, or half of all women who have undergone hysterectomy, are being screened unnecessarily.

106 1083 women women who underwent RRSO without hysterectomy at a median age 45.6 (IQR: 40.9 - 52.5), 8

107 en who underwent bilateral oophorectomy with hysterectomy at age </= 40 years had significantly reduc

108 d pathology reports from women who underwent hysterectomy at our institution for endometrial or endoc

109 when discussing the advantages and risks of hysterectomy at the time of RRSO in BRCA1+ women.

110 hough a quarter of US women undergo elective hysterectomy before menopause, controlled trials that ev

111 31, 2012, and underwent a benign, nongravid hysterectomy between January 1, 1996, and December 31, 2

112 dy was to determine the associations between hysterectomy, bilateral salpingo-oophorectomy (BSO), and

113 selected cardiac, hip/knee arthroplasty, and hysterectomy cases.

114 At hysterectomy, cervical cultures remained positive in 12

115 Vaginal delivery, hysterectomy, chronic straining, normal ageing, and abno

116 S women 18 years and older who had undergone hysterectomy (combined n = 188,390) was studied.

117 th, and cost for women who underwent robotic hysterectomy compared with both abdominal and laparoscop

118 ication rate was higher after robot-assisted hysterectomy compared with laparoscopic hysterectomy (23

119 er in BRCA+ women who underwent RRSO without hysterectomy compared with rates expected from the Surve

120 dometrial cancer, the use of total abdominal hysterectomy compared with total laparoscopic hysterecto

121 rious sequelae (eg, amniotic fluid embolism, hysterectomy), complications requiring intensive care un

122 ctive covariates, the risk of ultrasound- or hysterectomy-confirmed leiomyomata was inversely associa

123 elative risk of self-reported ultrasound- or hysterectomy-confirmed uterine leiomyomata according to

124 follow-up, 2,279 new cases of ultrasound- or hysterectomy-confirmed uterine leiomyomata were self-rep

125 ective surgical or interventional treatment (hysterectomy, curettage, ovary excision, or excision of

126 sis with clinical censoring information (ie, hysterectomy, death, or left the health plan) on all coh

127 The rates of abdominal hysterectomy decreased both in hospitals where robotic-a

128 ibroids is surgical removal by myomectomy or hysterectomy, depending in part on the desire for future

129 evidence of uterine AVM managed by abdominal hysterectomy, describing the imaging features on ultraso

130 Minimally invasive hysterectomy does not appear to compromise long-term sur

131 CGIN); if all or nearly all women had reflex hysterectomy done soon after initial treatment; if women

132 years old and had not undergone menopause or hysterectomy during followup.

133 tomy = 0.50, intestinal-endovascular = 0.36, hysterectomy-endovascular = 0.54, all P < 0.05).

134 Premenopausal hysterectomy, even without ovary removal, may reduce the

135 teral oophorectomy is often performed during hysterectomy for benign conditions and can reduce breast

136 Although robotically assisted hysterectomy for benign gynecologic conditions has been

137 07 and 2010, the use of robotically assisted hysterectomy for benign gynecologic disorders increased

138 ompare laparoscopic hysterectomy and robotic hysterectomy for endometrial cancer.

139 sue from the cervices of 99 women undergoing hysterectomy for reasons unrelated to epithelial abnorma

140 the potential benefits of minimally invasive hysterectomy for uterine cancer, population-level data d

141 ese findings support the use of laparoscopic hysterectomy for women with stage I endometrial cancer.

142 second branch of the WHI in women with prior hysterectomy found an even stronger correlation between

143 ith stage I-III uterine cancer who underwent hysterectomy from 2006 to 2011.

144 usal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly a

145 At 6 months, women in the hysterectomy group had greater improvement in MCS scores

146 to those reported by women randomized to the hysterectomy group.

147 with women without hysterectomy, women with hysterectomy had a significantly higher risk of diabetes

148 Women with a hysterectomy had a worse risk profile and higher prevale

149 At baseline, women with either type of hysterectomy had less favorable values for CVD risk fact

150 Robotically assisted and laparoscopic hysterectomy had similar morbidity profiles, but the use

151 ng tubal ligation, oophorectomy, and partial hysterectomy have been demonstrated using current commer

152 d equine estrogens alone in women with prior hysterectomy (hazard ratio, 1.17; CI, 1.00-1.36; P=0.045

153 y increased from 0.5% in 2007 to 9.5% of all hysterectomies in 2010.

154 agonist, accelerated GI recovery after BR or hysterectomy in 3 phase III trials.

155 assurance to women and their clinicians that hysterectomy in midlife is unlikely to accelerate the CV

156 Despite being the primary cause of hysterectomy in the United States, accounting for up to

157 omyomata (fibroids) are the leading cause of hysterectomy in the United States.

158 ctive age and are the primary indication for hysterectomy in the USA.

159 recorded in 560,356 participants (without a hysterectomy) in the UK Million Women Study of whom 4067

160 rine leiomyomata, confirmed by ultrasound or hysterectomy, in association with selected reproductive

161 nopausal women, aged 50-79 years, with prior hysterectomy, including 23% of minority race/ethnicity.

162 file at baseline compared with women with no hysterectomy, including a higher proportion of hypertens

163 Use of robotically assisted hysterectomy increased from 0.5% in 2007 to 9.5% of all

164 terectomy; performance of minimally invasive hysterectomy increased from 9.3% in 2006 to 61.7% in 201

165 Our results suggest that hysterectomy is associated with increased risk of kidney

166 tions (BRCA+ women), the role of concomitant hysterectomy is controversial.

167 Multivariate models suggest that hysterectomy is not the major determinant of this outcom

168 Hysterectomy is possibly protective against any stroke.

169 Hysterectomy is still the most commonly performed proced

170 orectal cancer resection, cesarean delivery, hysterectomy, knee replacement, hip replacement, and hip

171 mpared with those who had minimally invasive hysterectomy (laparoscopic and robot-assisted).

172 soring occurred at uterine cancer diagnosis, hysterectomy, last follow-up, or death.

173 ased risk of complications when undergoing a hysterectomy later in life.

174 ons, and blood transfusion when undergoing a hysterectomy later in life.

175 omy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectomy, or prostat

176 uggests that HT use among women who have had hysterectomies may negate the protective effects of hyst

177 t increased risk of diabetes associated with hysterectomy may be due to residual confounding, such as

178 Compared with women who underwent abdominal hysterectomy, minimally invasive hysterectomy was associ

179 Women who had had hysterectomies (n = 10,272) were randomly assigned to re

180 Those who had not had hysterectomies (n = 16,049) were randomly assigned to re

181 ctomy (n = 97,780), colectomy (n = 118,407), hysterectomy (n = 26,639), or radical prostatectomy (n =

182 ated equine estrogens only if they had prior hysterectomy (N=10 739).

183 Sera/FT were collected at hysterectomy (n=21).

184 g hip and knee replacement, cholecystectomy, hysterectomy, nonaccess vascular and cardiac procedures,

185 ctomies may negate the protective effects of hysterectomy on EOC, creating the appearance of a null o

186 risk of diabetes was similar for women with hysterectomy only and for women with hysterectomy with c

187 at first and last births, age at menopause, hysterectomy, oophorectomy, hormone therapy use, and bod

188 combined CHD compared with not having had a hysterectomy/oophorectomy (1.51; 1.34-1.71).

189 D could be explained by greater frequency of hysterectomy/oophorectomy and earlier age at surgery aft

190 were used to assess the association between hysterectomy/oophorectomy status and diabetes incidence.

191 Having had a hysterectomy/oophorectomy was associated with higher ris

192 Hysterectomy/oophorectomy was associated with higher ris

193 lvic procedures (cholecystectomy, colectomy, hysterectomy/oophorectomy, and prostatectomy) between 19

194 No women had hysterectomies or died.

195 fy high-risk patients likely to need radical hysterectomy or confirm the absence of residual tumor in

196 rticipants were randomly assigned to undergo hysterectomy or expanded medical treatment with estrogen

197 at menarche, age at menopause, or history of hysterectomy or oophorectomy.

198 idity and mortality in women and may vary by hysterectomy (or oophorectomy) status.

199 my (OR, 0.58 [95% CI, 0.55-0.61]; P < .001), hysterectomy (OR, 0.44 [95% CI, 0.37-0.53]; P < .001), a

200 otherapy (OR, 1.82; P = .0009), and previous hysterectomy (OR, 1.34; P = .0459).

201 y (OR, 1.45; 95% CI, 1.33-1.56; P < 0.0001), hysterectomy (OR, 1.70; 95% CI, 1.55-1.87; P < 0.0001),

202 east cancer risk, but either oophorectomy or hysterectomy, or both, and the timing of these procedure

203 omy, total nephrectomy, partial nephrectomy, hysterectomy, or oophorectomy at 1370 hospitals in the U

204 lstilbestrol by participant's mother, age at hysterectomy, or use of oral contraceptives.

205 incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years.

206 y was $10,618 versus $8,996 for laparoscopic hysterectomy (P < .001).

207 oscopic hysterectomy versus 8.1% for robotic hysterectomy (P = .13).

208 show significant differences between radical hysterectomy patients and controls on any of the outcome

209 patients (451 bowel resection and 18 radical hysterectomy patients).

210 For hysterectomy, patients at hospitals in moderately (3.75

211 165 (34.3%) who underwent minimally invasive hysterectomy; performance of minimally invasive hysterec

212 ) were less likely to perform a simultaneous hysterectomy (performed in 11.5% vs 16.5% of patients; s

213 t: A forty-year-old female with a history of hysterectomy presenting with vague abdominal pain was co

214 areas were less likely to undergo a robotic hysterectomy procedure (P < .05 for all).

215 theast were more likely to undergo a robotic hysterectomy procedure, whereas black women, those witho

216 joint replacement, vascular, colorectal, and hysterectomy procedures during the period from 1 October

217 During the same time period, laparoscopic hysterectomy rates increased from 24.3% to 30.5%.

218 lacebo (n = 84); all women who had not had a hysterectomy received 100 mg/d of oral micronized proges

219 Women with prior hysterectomy received CEE alone (0.625 mg/d) (n = 5310)

220 Women with prior hysterectomy received oral conjugated equine estrogen (0

221 Women with a hysterectomy (regardless of oophorectomy status) had an

222 Hysterectomy (regardless of oophorectomy status) was a s

223 r large, prospective study, we observed that hysterectomy, regardless of oophorectomy status, was ass

224 endations), 68.5% of women who had undergone hysterectomy reported having had a Pap smear in the past

225 n US women 18 years and older have undergone hysterectomy, representing 21% of the population.

226 ysterectomy compared with total laparoscopic hysterectomy resulted in equivalent disease-free surviva

227 The hysterectomy route and medical regimen were determined b

228 ocolpopexy (RALS) and robot-assisted radical hysterectomy (RRH) to their conventional laparoscopic an

229 findings provide reassurance for women with hysterectomy seeking relief of climacteric symptoms in t

230 Restricting the analyses to women with prior hysterectomy somewhat strengthened the associations, alb

231 on for women without residual disease in the hysterectomy specimen and for women with grade 1 or 2 ca

232 HESCs were isolated from hysterectomy specimens from normally cycling premenopaus

233 Evidence suggests that hysterectomy status with or without bilateral oophorecto

234 ancer were calculated, stratified by age and hysterectomy status, and adjusted by area of residence,

235 lack, 2.2% Hispanic/Latina, and 3.6% other), hysterectomy status, and date of blood draw.

236 In 48 patients who underwent hysterectomy, surgical pathologic findings were the refe

237 ctomy (TLH) is equivalent to total abdominal hysterectomy (TAH) in women with treatment-naive endomet

238 rmin-treated group, Ki-67 was 12.9% lower at hysterectomy than at recruitment (95% CI 3.7-22.1, p=0.0

239 Black women experience higher rates of hysterectomy than other women in the United States.

240 nd American Indian women had higher rates of hysterectomy than white women (52.9%, 44.6%, and 49.2% v

241 may have preceded a recent hysterectomy and hysterectomies that spared the cervix or were performed

242 Apart from hysterectomy, there is no consensus recommendation for r

243 Other than a prior history of hysterectomy, there was no relevant medical history.

244 To investigate whether total laparoscopic hysterectomy (TLH) is equivalent to total abdominal hyst

245 s, the readmission rate ranged from 3.8% for hysterectomy to 14.9% for lower extremity vascular bypas

246 igned 10,739 postmenopausal women with prior hysterectomy to conjugated equine estrogen (CEE; 0.625 m

247 iatric procedures, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral he

248 rgans, including the bladder, uterus or post-hysterectomy vaginal cuff, and the small or large bowel,

249 complication rate was 9.8% for laparoscopic hysterectomy versus 8.1% for robotic hysterectomy (P = .

250 oophorectomy, 0.88 (95% CI, 0.85-0.90) after hysterectomy vs no hysterectomy, 1.63 (95% CI, 1.52-1.75

251 The mean cost for robotic hysterectomy was $10,618 versus $8,996 for laparoscopic

252 dds ratio (OR) for any morbidity for robotic hysterectomy was 0.76 (95% CI, 0.56 to 1.03).

253 t abdominal hysterectomy, minimally invasive hysterectomy was associated with a lower overall complic

254 ver users of estrogen-only HT, premenopausal hysterectomy was associated with a significantly decreas

255 Premenopausal hysterectomy was inversely associated with the odds of E

256 Hysterectomy was not associated with risk factors for CV

257 sed both in hospitals where robotic-assisted hysterectomy was performed as well as in those where it

258 dure at hospitals where robotically assisted hysterectomy was performed, robotically assisted hystere

259 In a multivariable model, robotic hysterectomy was significantly more costly ($1,291; 95%

260 nd dissatisfaction with medroxyprogesterone, hysterectomy was superior to expanded medical treatment

261 aims of decreased complications with robotic hysterectomy, we found similar morbidity but increased c

262 ared with placebo in women who had undergone hysterectomy, we performed computed tomography of the he

263 Data about timing, type, and indication for hysterectomies were obtained from the Nationwide Inpatie

264 l costs associated with robotically assisted hysterectomy were $2189 (95% CI, $2030-$2349) more per c

265 Women who had undergone a hysterectomy were at a significantly elevated kidney can

266 Patients who underwent abdominal hysterectomy were compared with those who had minimally

267 gh patients who underwent a robotic-assisted hysterectomy were less likely to have a length of stay l

268 nts scheduled for bowel resection or radical hysterectomy were randomized (1:1:1) to receive alvimopa

269 opausal women aged 50 to 79 years with prior hysterectomy were randomized to CEE or placebo at 40 US

270 6,608 postmenopausal women who had not had a hysterectomy were randomized to CEE plus medroxyprogeste

271 739 postmenopausal women who had undergone a hysterectomy were randomized to conjugated equine estrog

272 on of 5.6 years, and 10,739 women with prior hysterectomy were randomized to conjugated equine estrog

273 rine leiomyomata, confirmed by ultrasound or hysterectomy, were reported.

274 random sample of women who have undergone a hysterectomy (WH) (n=573) with the HPV prevalence in age

275 as the proportion of women with a history of hysterectomy who reported a current Pap smear (within 3

276 VD) before and after natural menopause (NM), hysterectomy with at least 1 ovary conserved (HOC), or h

277 my with at least 1 ovary conserved (HOC), or hysterectomy with bilateral oophorectomy (HBSO).

278 though research indicates that premenopausal hysterectomy with bilateral oophorectomy decreases the r

279 th ovarian conservation, and 106 women had a hysterectomy with bilateral oophorectomy.

280 These findings suggest that prophylactic hysterectomy with bilateral salpingo-oophorectomy is an

281 Compared with hysterectomy alone, hysterectomy with BSO was not associated with additional

282 en with hysterectomy only and for women with hysterectomy with concomitant BSO.

283 were restricted to women who had undergone a hysterectomy with or without an oophorectomy.

284 scular disease (CVD) leading up to and after hysterectomy with or without bilateral oophorectomy with

285 Hysterectomy with or without ovarian conservation is not

286 therapy with ERT or placebo after undergoing hysterectomy with or without pelvic and aortic nodal sam

287 Hysterectomy with ovarian conservation (OR = 0.83, 95% C

288 ad reached natural menopause, 77 women had a hysterectomy with ovarian conservation, and 106 women ha

289 ervation (OR = 0.83, 95% CI: 0.72, 0.96) and hysterectomy with partial ovary removal (OR = 0.73, 95%

290 for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not h

291 y age for cervical cancer if they have had a hysterectomy with removal of the cervix.

292 physical activity, medications, and previous hysterectomy (with or without oophorectomy).

293 nopausal women who had and had not undergone hysterectomy, with or without oophorectomy.

294 en randomized to medicine elected to undergo hysterectomy, with similar and lasting quality-of-life i

295 nopausal surgery, bilateral oophorectomy and hysterectomy without oophorectomy were associated with l

296 60, 95% confidence interval: 0.47, 0.77; for hysterectomy without oophorectomy, multivariable-adjuste

297 ancer in black women, it remains unclear how hysterectomy without ovary removal affects risk, whether

298 act cervices (women who have not undergone a hysterectomy [WNH]) (n=581) participating in a study at

299 Compared with women without hysterectomy, women with hysterectomy had a significantl

300 tility in women, and a common indication for hysterectomy, yet the disease remains poorly diagnosed a